{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:18:10Z","timestamp":1769548690498,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["Cohen19AC0"],"award-info":[{"award-number":["Cohen19AC0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["chestpulmonary.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST Pulmonary"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.chpulm.2024.100099","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T07:40:07Z","timestamp":1725694807000},"page":"100099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Clinical Efficacy of Elexacaftor-Tezacaftor-Ivacaftor in People With Cystic Fibrosis and Preexisting Advanced Lung Disease at Treatment Initiation"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-1110","authenticated-orcid":false,"given":"Leah A.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6286-5921","authenticated-orcid":false,"given":"Gregory A.","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8062-893X","authenticated-orcid":false,"given":"April R.","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4549-8036","authenticated-orcid":false,"given":"Bryan","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-8505","authenticated-orcid":false,"given":"Christina M.","family":"Mingora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10212","key":"10.1016\/j.chpulm.2024.100099_bib1","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.chpulm.2024.100099_bib2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.chpulm.2024.100099_bib3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jcf.2021.05.009","article-title":"Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease","volume":"20","author":"B","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.chpulm.2024.100099_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid\u00a0Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.chpulm.2024.100099_bib5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.chpulm.2024.100099_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106646","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del\/minimal function genotype","volume":"189","author":"Carnovale","year":"2021","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chpulm.2024.100099_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcf.2022.01.012","article-title":"Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis","volume":"21","author":"Martin","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.chpulm.2024.100099_bib8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/ph15050606","article-title":"Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study","volume":"15","author":"Migliorisi","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.chpulm.2024.100099_bib9","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.chest.2017.01.019","article-title":"Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV(1) < 30% of Predicted in the United States","volume":"151","author":"Ramos","year":"2017","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chpulm.2024.100099_bib10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","article-title":"Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease","volume":"19","author":"Kapnadak","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.chpulm.2024.100099_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.03.002","article-title":"Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines","volume":"18","author":"Ramos","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.chpulm.2024.100099_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chpulm.2024.100099_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1171544","article-title":"Spirometric and anthropometric improvements in response to elexacaftor\/tezacaftor\/ivacaftor depending on age and lung disease severity","volume":"14","author":"Schutz","year":"2023","journal-title":"Front Pharmacol"},{"issue":"18","key":"10.1016\/j.chpulm.2024.100099_bib14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJM199204303261804","article-title":"Prediction of mortality in patients with cystic fibrosis","volume":"326","author":"Kerem","year":"1992","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.chpulm.2024.100099_bib15","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1038\/s41598-020-63590-8","article-title":"Evaluation of a five-year predicted survival model for cystic fibrosis in later time periods","volume":"10","author":"Liou","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.chpulm.2024.100099_bib16","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.chpulm.2024.100099_bib17","series-title":"Patient registry annual data report","year":"2021"},{"issue":"2","key":"10.1016\/j.chpulm.2024.100099_bib18","first-page":"281","article-title":"CFTR modulators: transformative therapies for cystic fibrosis","volume":"27","author":"Dwight","year":"2021","journal-title":"J Manag Care Spec Pharm"}],"container-title":["CHEST Pulmonary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949789224000655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949789224000655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T04:16:44Z","timestamp":1757650604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949789224000655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2949789224000655"],"URL":"https:\/\/doi.org\/10.1016\/j.chpulm.2024.100099","relation":{},"ISSN":["2949-7892"],"issn-type":[{"value":"2949-7892","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Clinical Efficacy of Elexacaftor-Tezacaftor-Ivacaftor in People With Cystic Fibrosis and Preexisting Advanced Lung Disease at Treatment Initiation","name":"articletitle","label":"Article Title"},{"value":"CHEST Pulmonary","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chpulm.2024.100099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100099"}}